Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes
2020-000551-12Phase 2Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of dasiglucagon in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Time in hypoglycemia (0-180 minutes post-intervention). Started Mar 2020; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2020-000551-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000551-12.